06.2.2023

Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer

Press Releases

05.25.2023

Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Press Releases

05.9.2023

Affini-T Therapeutics to Present Novel CRISPR Gene Editing Data from its Oncogenic Driver Program Targeting KRAS at the American Society of Gene and Cell Therapy 26th Annual Meeting

Press Releases

04.13.2023

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023

Press Releases

04.13.2023

Affini-T Therapeutics Announces Licensing Agreement with Leading Comprehensive Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs

Press Releases

04.6.2023

Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023

Press Releases

03.3.2023

Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS

Press Releases

01.5.2023

Affini-T Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Press Releases

11.15.2022

ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

Press Releases

11.7.2022

Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Press Releases

09.22.2022

Affini-T Therapeutics Named to the 2022 Endpoints 11

Press Releases

07.26.2022

Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer

Press Releases

07.11.2022

Affini-T Therapeutics Appoints Jill DeSimone to its Board of Directors

Press Releases

06.15.2022

Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients

Press Releases

06.8.2022

Affini-T Therapeutics to Present at Upcoming Investor and Industry Conferences

Press Releases

06.2.2022

Clinical Strategy for Enhancing Affini-T Therapeutics’ Merkel Polyoma Virus TCR Therapy to be Presented at ASCO 2022

Press Releases

05.3.2022

Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy

Press Releases

04.5.2022

Affini-T Expands Board of Directors with Appointments of Michael Varney, Ph.D., and Daniel Faga

Press Releases

03.22.2022

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Press Releases

01.10.2022

Affini-T Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Press Releases